Clinical Trial

A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase Ib/II clinical study. All participants are patients with advanced colorectal cancer (CRC). The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary anti-tumor efficacy of HDM2017 in combination with standard of care in patients with advanced CRC.
Trial Details
NCT Number NCT07621159
Lead Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions Colorectal Cancer Metastatic
Enrollment 120 participants
Start Date 2026-07-15
Primary Completion 2027-11-01 (estimated)
Study Completion 2028-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-02